Genmab — Juni 2015
-
Pyt med hvornår milestensbetalingen falder. Det vigtige er at processen er sat i gang og at: "FDA tildeler denne form for ansøgningsprocedure, hvis de efter en foreløbig evaluering af kliniske data vurderer, at den pågældende
breakthrough behandling kan være effektiv, og derfor overvejer at behandle dele af ansøgningen, før indleveringen er komplet." -
Enig Fantomas og Bulder.
-
God morgen.

-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind